What the FDA labels say about taking them together
Rifampin and teriflunomide
Teriflunomide's FDA label of February 20, 2026 names rifampin in its drug interactions section; the rifampin label PlainMeds reads does not name teriflunomide. The teriflunomide label: “For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family, especially HMG-Co reductase inhibitors, consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of …”
Check it at the source: the rifampin FDA label on DailyMed (effective February 11, 2026, Lupin Pharmaceuticals, Inc.); the teriflunomide FDA label on DailyMed (effective February 20, 2026, Genzyme Corporation).
What does the rifampin label say about teriflunomide?
Rifampin's label (effective February 11, 2026) does not name teriflunomide in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (rifampin), Lupin Pharmaceuticals, Inc., effective February 11, 2026 (SPL set b56004f0-f23d-47f6-80c7-39884fccbccc), via openFDA; the full label on DailyMed
What does the teriflunomide label say about rifampin?
Teriflunomide label, drug interactionsFor other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking AUBAGIO [see Clinical Pharmacology (12.3) ].
Source: FDA drug label (Aubagio), NDA202992 (Sanofi Aventis Us), as published by Genzyme Corporation, effective February 20, 2026 (SPL set 4650d12c-b9c8-4525-b07f-a2d773eca155), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Rifampin | Teriflunomide | |
|---|---|---|
| Labeled for | n/a | Multiple sclerosis |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.679 per capsule 300 mg capsule | $0.233 per tablet 14 mg tablet |
| Shortage now | In shortage | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once